Pre-Market Pulse on Biotechnology Stocks -- Inovio Pharma, Vital Therapies, Regulus Therapeutics, and Northwest Biotherapeutics
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Inovio Pharmaceuticals Inc. (INO), Vital Therapies Inc. (VTL), Regulus Therapeutics Inc. (RGLS), and Northwest Biotherapeutics Inc. (NWBO). Free research report on Inovio Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
Inovio Pharmaceuticals Inc.'s stock advanced 3.78%, to close the day at $6.87. The stock recorded a trading volume of 6.63 million shares, much above its three months average volume of 1.24 million shares. Inovio Pharmaceuticals Inc.'s shares have declined 5.76% in the previous three months and 25.16% since the beginning of 2015. However, the stock has advanced 2.08% in the last one month. The company's shares are trading 3.31% above their 50-day moving average. Additionally, Inovio Pharmaceuticals Inc. has a Relative Strength Index (RSI) of 54.03. Sign up and read the free notes on INO at:
http://www.parklaneadvisor.com/
On Friday, shares in Vital Therapies Inc. recorded a trading volume of 1.61 million shares, higher than their three months average volume of 0.58 million shares. The stock ended the day 1.47% lower at $10.07. Vital Therapies Inc.'s stock has surged 33.91% in the last one month and 159.54% in the previous three months. However, the stock has plummeted 59.61% on YTD basis. The company is trading above its 50-day moving average by 23.97%. Furthermore, shares of Vital Therapies Inc. have an RSI of 60.14. The complimentary notes on VTL can be downloaded in PDF format at:
http://www.parklaneadvisor.com/
Regulus Therapeutics Inc.'s stock finished Friday's session 6.59% higher at $9.38. A total of 0.83 million shares were traded, which was above its three months average volume of 0.55 million shares. Over the last one month and since the beginning of this year, Regulus Therapeutics Inc.'s shares have declined 3.89% and 41.52%, respectively. However, the stock has gained 10.22% in the previous three months. The company's shares are trading above their 50-day moving average by 12.39%. Regulus Therapeutics Inc.'s stock has an RSI of 55.79. Register for free on Park Lane Advisor and access the latest research on RGLS at:
http://www.parklaneadvisor.com/
On Friday, shares in Northwest Biotherapeutics Inc. ended the session 4.28% higher at $4.39. The stock reported a trading volume of 0.58 million shares, above its three months average volume of 0.46 million shares. Northwest Biotherapeutics Inc.'s shares have declined 4.36% in the last one month, 43.57% in the previous three months and 17.94% on YTD basis. The company is trading 9.26% below its 50-day moving average and 43.85% below its 200-day moving average. Moreover, shares of Northwest Biotherapeutics Inc. have an RSI of 47.38. The complete research on NWBO is available for free at:
http://www.parklaneadvisor.com/
About Park Lane Advisor:
Park Lane Advisor ("PLA") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. PLA has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PLA has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY:
PLA, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING:
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PLA nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.ParkLaneAdvisor.com
RESTRICTIONS:
PLA is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT:
For any questions, inquiries, or comments reach out to us directly at:
E-mail: media (at) ParkLaneAdvisor (dot) com
SOURCE: Park Lane Advisor
